Feb 29, 2016 8:00 am EST Atara Bio to Present at the Cowen and Company 36th Annual Health Care Conference
Feb 08, 2016 8:00 am EST Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD)
Dec 14, 2015 6:00 am EST Atara Bio Announces Results From the Phase 2 Proof-of-Concept PINTA 745 Clinical Trial for Protein Energy Wasting in Patients With End Stage Renal Disease
Dec 06, 2015 9:00 am EST Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes (CMV-CTL), a Novel Approach to Adoptive Immunotherapy, to Treat Patients With Refractory CMV Disease in the Central Nervous System (CNS)
Dec 05, 2015 12:00 pm EST Atara Bio Announces Positive Results From Phase 1 Clinical Trial of Wilms’ Tumor 1 Targeted Cytotoxic T Lymphocytes (WT1-CTL) Product Candidate in Hematologic Malignancies
Nov 05, 2015 9:20 am EST Atara Bio’s Collaborating Investigators to Present Data From Two Cellular Therapy Product Candidates at the American Society of Hematology (ASH) Annual Meeting 2015